Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd (Stock Code: DRREDDY)

Please find enclosed a Press Release on "Dr.

Reddy's launches drug-free migraine management device Nerivio in Europe following successful launch in India."

This is for your information and records.

For Dr. Reddy's Laboratories Limited

Company Secretary, Compliance Officer and Head-CSR

launches drug-free migraine management device Nerivio in Europe following successful launch in India

Hyderabad India; April 10, 2024 - Dr.

Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy's"),

a global pharmaceutical company, announced the launch of the drug-free non-invasive migraine management wearable device Nerivio in

Germany through its step-down subsidiary betapharm. The launch marks the company's entry into digital therapeutics in Europe. Nerivio

is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Nerivio was presented in 2023 by Dr. Reddy's

at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held

in Barcelona, Spain. Dr. Reddy's will present and launch Nerivio during the Neurological Association of South Africa annual

congress on April 17, 2024, in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine - Dartmouth,

and Vice President, New England Institute for Neurology and Headache. In May 2024, Nerivio will also be presented at International

Headache Society 2024 iHEAD meeting in Berlin, Germany. In subsequent months, Dr. Reddy's will launch Nerivio in Spain and

Last year, Dr. Reddy's entered into an exclusive

agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other

pain conditions, for the marketing and distribution of Nerivio in multiple markets.

Migraine is a global health challenge, affecting around

30% of adults on 15 or more days per month, impacting 1.7% to 4% of the population1. The current best estimate of global migraine

prevalence is 14-15%, and, in terms of burden, migraine accounts for 4.9% of global ill health, quantified as years lived with disability2.

Migraines are known to have a disproportionate impact on women. Around 8 to 10 million people in Germany are affected, 14.8% of women

and 6.0% of men3. In India, women constitute approximately 60% of the 213 million migraine sufferers in India4.

Dr. Reddy's launched Nerivio in India in

2023. In India, Nerivio is supported by Dr. Reddy's unique patient support programme called M-Free'. The programme

is a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes services such as onboarding

and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer

care to help patients get the most out of the device. With lifestyle modification as a key recommendation for better management of migraine,

M-Free awareness program offers a suite of value-add services such as nutritionist consultation, yoga and meditation sessions with certified

specialists for holistic medicine free migraine management.

M.V. Ramana, Chief Executive Officer, Branded Markets

(India and Emerging Markets), Dr. Reddy's said, "At a time when conversations on migraine focus on migraine5

as a women's health issue, relief from migraine through the use of technology and drug-free solutions, challenges associated with

managing migraine during the child-bearing age, and distinguishing migraine from headache, we are happy to take our clinically-proven

first digital therapeutics product, Nerivio , to patients in our identified markets. Nerivio has had an encouraging start in

India, with recommendation from neurologists in India and bringing relief to patients living with migraine. We believe this product meets

a genuine unmet clinical need among migraine patients, and has the potential to reduce pill burden in migraine. We look forward to receiving

patient and HCP feedback from these markets."

About Nerivio and its clinically-proven benefits:

The Nerivio experience has so far benefited over

45,000 patients globally. It is backed by robust clinical evidence from 19,000+ patients as an acute and preventive treatment option in

1 https://www.neurologyindia.com/article.asp?issn=0028-3886;year=2021;volume=69;issue=7;spage=4;epage=9;aulast=Krishnan

2 Steiner, T.J., Stovner, L.J. Global epidemiology of migraine

and its implications for public health and health policy. Nat Rev Neurol 19, 109-117 (2023). https://doi.org/10.1038/s41582-022-00763-1

3 Porst et al. J Health Monitoring 2020 5(S6):2-26

4 https://en.gaonconnection.com/india-migraine-stroke-2019-lancet-health-air-pollution-blood-pressure-headache-health-neurological-disorders/

5 https://www.dailypioneer.com/2024/state-editions/why-women-are-thrice-more-at-risk-of-migraines-than-men---.html

6 Data on file; https://nerivio.com/link-directory/

Nerivio is a prescription-based non-invasive

device intended for acute and prophylactic (preventive) treatment of migraine with or without aura7 for adults and adolescents

aged 12 years and above. Nerivio can be worn on the upper arm. Each device has in-built 18 x 45-minute treatment sessions. It is

to be used within 60 minutes of onset of headache or aura for acute treatment of migraine or every alternate day for prevention of migraine.

The device uses the Remote Electrical Neuromodulation (REN) mechanism to specifically activate conditioned pain modulation by stimulating

nerve endings. This initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects

the original source of migraine pain in the head8. The unique device is accompanied by the Nerivio app, which is user-friendly and

freely available on Google Play Store and the Apple app store for download. The app can be used to control the intensity levels of the

device, and to track progression through the in-built digital diary.

Clinically proven9 and safe, Nerivio

is suitable for a wide range of patients, including those who prefer drug-free options, individuals with contraindications to medications

or poor medication tolerance, sensitive populations such as adolescents, women of child-bearing age, and patients at risk of medication

overuse headache10. Studies show that Nerivio is safe and well tolerated with no systemic side effects or concern for

medication overuse. It has been evaluated in robustly designed pivotal studies conducted in the U.S., in patients seeking effective acute

or preventive treatment of migraine. Nerivio has proven efficacy in not only effectively relieving pain and reducing monthly migraine

days, but also associated symptoms in migraine such as nausea, vomiting etc. It has been shown to reduce the need for drugs used for acute

treatment in nearly 9 out of 10 patients11. Being an effective non-invasive therapy, the associated adverse events are not

a concern. This is extremely useful in patients seeking preventive treatment of migraine since many patients experience tolerability issues

with drugs, resulting in significant impact on their quality of life, when used for long time (>3 months)12.

Nerivio is a prescription-based product. Patients

are advised to consult their neurologists on the use of the device and management of migraine. For more queries, doctors and patients

can call the dedicated helpline number 1800-123-2360 (toll-free) or email us at neriviodrl@porteamedical.com or WhatsApp on 6366881900.

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,

India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good

Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars

and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep

science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter

of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high

in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

7 Symptoms or sensations, such as flashing lights

or zigzag lines or loud sound, which typically precede migraine headache

8 https://nerivio.com/how-it-works/

9 https://nerivio.com/

10 Babaei M, Rapoport AM. Expert Review of Medical

Devices. 2023 May 12:1-5.

11 MarmuraMJ et al. Front Neurol. 2020 Apr 7;11:226.